


PHARMACEUTICAL 2021



ARROWHEAD PHARMACEUTICALS of arrowhead pharmaceuticals INC.



Rank 85 of 409





PHARMACEUTICAL 2021



ARROWHEAD PHARMACEUTICALS of arrowhead INC.



Rank 85 of 409

The relative strengths and weaknesses of ARROWHEAD PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARROWHEAD PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 111% points. The greatest weakness of ARROWHEAD PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 411% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	322,370
Cost of Goods Sold	0
Intangible Assets	15,363
Liabilities, Current	40,681
Liabilities, Non-Current	20,043
Other Assets	153,889
Other Compr. Net Income	410
Other Expenses	2.4
Other Liabilities	0
Other Net Income	8,608
Property and Equipment	30,881
Research and Development	128,875
Revenues	87,992
Selling, General and Administrative Expense	52,276

Output Variable	Value in 1000 USD
Assets	522,504
Liabilities	60,725
Expenses	181,153
Stockholders Equity	461,779
Net Income	-84,553
Comprehensive Net Income	-84,348
Economic Capital Ratio	57%